Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.
Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, Schaller E, Herrmann I, Wolf A, Urbig T, Baeuerle PA, Kufer P. Lutterbuese R, et al. Among authors: rattel b. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12605-10. doi: 10.1073/pnas.1000976107. Epub 2010 Jun 28. Proc Natl Acad Sci U S A. 2010. PMID: 20616015 Free PMC article.
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, Kischel R, Hoffmann P, Brandl C, Schuhmacher J, Mueller P, Finnern R, Fuergut M, Zopf D, Slootstra JW, Baeuerle PA, Rattel B, Kufer P. Friedrich M, et al. Among authors: rattel b. Mol Cancer Ther. 2012 Dec;11(12):2664-73. doi: 10.1158/1535-7163.MCT-12-0042. Epub 2012 Oct 5. Mol Cancer Ther. 2012. PMID: 23041545
Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, Wahl J, Hoffmann P, Kischel R, Kvesic M, Slootstra JW, Baeuerle PA, Kufer P, Rattel B. Friedrich M, et al. Among authors: rattel b. Mol Cancer Ther. 2014 Jun;13(6):1549-57. doi: 10.1158/1535-7163.MCT-13-0956. Epub 2014 Mar 27. Mol Cancer Ther. 2014. PMID: 24674885
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
Deegen P, Thomas O, Nolan-Stevaux O, Li S, Wahl J, Bogner P, Aeffner F, Friedrich M, Liao MZ, Matthes K, Rau D, Rattel B, Raum T, Kufer P, Coxon A, Bailis JM. Deegen P, et al. Among authors: rattel b. Clin Cancer Res. 2021 May 15;27(10):2928-2937. doi: 10.1158/1078-0432.CCR-20-3725. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504551
The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated.
Plater-Zyberk C, Lopes Estêvão DM, d'Argouges S, Haanstra KG, Kondova I, Vierboom M, Boehm T, Neef R, Vieser EM, Rattel B, Baeuerle PA, Jonker M. Plater-Zyberk C, et al. Among authors: rattel b. Transpl Immunol. 2011 Sep;25(2-3):133-40. doi: 10.1016/j.trim.2011.06.003. Epub 2011 Jun 25. Transpl Immunol. 2011. PMID: 21708251
Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule.
Pham E, Friedrich M, Aeffner F, Lutteropp M, Mariano NF, Deegen P, Dahlhoff C, Vogel F, Bluemel C, Harrold JM, Brandl C, Grinberg N, Rattel B, Coxon A, Bailis JM. Pham E, et al. Among authors: rattel b. Mol Cancer Ther. 2021 Oct;20(10):1977-1987. doi: 10.1158/1535-7163.MCT-21-0236. Epub 2021 Aug 10. Mol Cancer Ther. 2021. PMID: 34376583
AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.
Goldstein RL, Goyos A, Li CM, Deegen P, Bogner P, Sternjak A, Thomas O, Klinger M, Wahl J, Friedrich M, Rattel B, Lamas E, Min X, Sudom A, Farshbaf M, Coxon A, Balazs M, Arvedson T. Goldstein RL, et al. Among authors: rattel b. Blood Adv. 2020 Sep 8;4(17):4180-4194. doi: 10.1182/bloodadvances.2020002565. Blood Adv. 2020. PMID: 32886754 Free PMC article.
26 results